The observation that cyclosporine inhibits HCV replication in vitro has led some programs to use cyclosporine as the calcineurin inhibitor (CNI) of choice after orthotopic liver transplantation (OLT). Previous studies comparing outcomes with different CNIs used small HCV cohorts or had short-term follow-up. We examined patient survival and fibrosis progression in all HCV-infected adult primary OLT recipients from 1995 to 2004 at the Annette C. and Harold C. Simmons Transplant Institute (n = 516). Patients were categorized by their CNI on day 7 post-OLT, and they were excluded if they died before day 14. Patient and donor age, sex, race, and prevalence of cytomegalovirus infection post-OLT were similar in the tacrolimus and cyclosporine patients. As expected, acute cellular rejection and steroid-resistant rejection were less common in tacrolimus-treated patients. Although no difference in 1-year survival was seen, tacrolimus patients (n = 268) had superior 5-year survival compared to cyclosporine patients (n = 248) (75% vs. 67%; P = 0.02). Fibrosis progression was no different between the groups. In our retrospective analysis of 516 post-OLT patients, tacrolimus improved long-term survival compared to cyclosporine in HCV-infected patients, although it did not impact HCV fibrosis progression. H epatitis C (HCV) viremia at the time of orthotopic liver transplant (OLT) leads to universal reinfection of the new graft and has been repeatedly shown to decrease graft and patient survival (1) (2) (3) (4) (5) (6) . When HCV viremia is eradicated pre-or post-OLT, a signifi cant survival advantage is achieved (7) . Although HCV infection can be treated with pegylated interferon and ribavirin, sustained virologic response post-OLT is infrequent (8) (9) (10) . Th erefore, transplant professionals often attempt to "optimize" immunosuppression when viral eradication is not possible. Toward this goal, some transplant centers switched their calcineurin inhibitor (CNI) of choice from tacrolimus to cyclosporine when in vitro data showed cyclosporine inhibited HCV viral replication (11) (12) (13) (14) (15) . In addition, earlier reports raised concern that tacrolimus might reduce the antiviral activity of interferon, although subsequent data did not confi rm this observation (16) . However, more important than in vitro information on HCV viral replication is how CNIs impact patient survival and HCV fi brosis progression.
To date, only large trials with short-term follow-up or small trials with longer-term follow-up have been published; no large trial of exclusively HCV-infected patients with 5-year follow-up has been performed to determine if CNI choice aff ects longterm patient survival and/or fi brosis progression post-OLT (17) (18) (19) (20) (21) (22) (23) . Toward this goal, we analyzed the survival and fi brosis progression of all our adult primary OLT patients with HCV infection from January 1995 to December 2004 based on CNI assigned by protocol at day 7.
METHODS
Institutional review board approval was granted prior to the initiation of this retrospective study. Th e Annette C. and Harold C. Simmons Transplant Institute maintains a prospective research database called the Liver Transplant Research Database System, which contains data on all OLT patients since the program's inception. Cause of death is obtained from death certificates and hospital records and is reviewed by a physician before it is entered into the database. Patients undergo protocol liver biopsies at year 1, 2, and 5; they have additional liver biopsies for abnormal liver function tests. All rejections are diagnosed by biopsy. Th e METAVIR fi brosis score of all liver biopsies is logged in the database regardless of indication. Pathology results were not rereviewed for the purposes of this study. Compliance with protocol liver biopsies was assessed: the number of patients who obtained a protocol liver biopsy was divided by those who should have obtained a protocol biopsy (defi ned as patients who were alive without previously meeting the endpoint of stage 3 or 4 fi brosis). Compliance at year 1, 2, and 5 was 88%, 74%, and 73%, respectively.
We examined patient survival and fi brosis progression in all adult primary OLT recipients from 1995 to 2004 (n = 516) who had a diagnosis of HCV and survived longer than 14 days. Patients were categorized by the CNI they received on day 7 post-OLT and excluded from the analysis if they were not on a CNI on day 7.
Patient characteristics were compared using Wilcoxon rank sum, and median values were reported. Patient survival and fi brosis progression were evaluated by Kaplan-Meier analysis. In addition, Cox proportional hazards analyses were used to assess risk factors for death and fi brosis progression. Stepwise multivariable models were built using factors from the univariate analysis that had a P value <0.1. Th e fi nal multivariable models included only factors that were statistically signifi cant. Statistical signifi cance was defi ned as a P < 0.05. SAS 9.1 was used for all statistical analyses. Table 1 compares the characteristics of patients transplanted for HCV treated with tacrolimus vs. cyclosporine between January 1995 and December 2004, who survived greater than 14 days post-OLT. Patients in both groups had a similar recipient and donor age, were mostly Caucasians of male sex, and had the same likelihood of cytomegalovirus (CMV) infection. In addition, both CNI groups were equally likely to remain on the CNI assigned by protocol on day 7 at week 4. Model for End-Stage Liver Disease (MELD; calculated MELD, not match MELD) at OLT was higher and cold ischemia time was shorter in the tacrolimus-treated patients. Tacrolimus-treated patients were more likely to receive mycophenolate mofetil instead of steroids for chronic immunosuppression and were less likely to experience rejection of any kind than cyclosporine-treated patients. Figure 1 demonstrates the survival advantage that tacrolimus-treated patients had over cyclosporine-treated patients (P = 0.02). Th is survival advantage was not appreciated until after year 1. Th e same survival advantage was also seen in patients without HCV (Figure 1b) (P < 0.001), although it was appreciated sooner post-OLT.
RESULTS
Kaplan-Meier analysis was undertaken to assess relevant factors associated with survival in the two groups (Table 2) . Acute cellular rejection, although decreased in incidence in tacrolimus-treated patients, does not explain the survival diff erence. Tacrolimus-treated patients without steroid-resistant rejection (SRR) had the best survival, and tacrolimus-treated patients with SRR had the worst survival, although SRR was uncommon in tacrolimus-treated patients (P = 0.007). All patients, regardless of race, achieved a survival advantage with tacrolimus; however, the survival advantage of tacrolimus treatment was greatest for African American recipients. Th e absolute survival advantage at 5 years between tacrolimus and cyclosporine was 22% for African Americans vs. 13% for other races and 6% for Caucasians (P = 0.04).
Since transplant survival improves when the pretransplant MELD is low (24), we compared the eff ect of CNI choice on the outcome of patients in diff erent MELD groups (Table  2) . A MELD of <21 was chosen arbitrarily to represent a low MELD. Th e survival advantage aff orded patients treated with tacrolimus rather than cyclosporine post-OLT was similar to the diff erence between high and low preoperative MELD score in the cyclosporine-treated patients (P = 0.002). We analyzed patients' risk of achieving the composite endpoint of fi brosis progression to advanced fi brosis (METAVIR stage 3 or 4) or death from HCV by Kaplan-Meier analysis (Figure 2) . Th e step increases seen in the Kaplan-Meier analysis correspond to protocol liver biopsy time points at years 1, 2, and 5. Th ere was no diff erence between the groups (P = NS).
Patients with hepatocellular carcinoma were treated under a separate protocol with low-dose cyclosporine and rapamycin, and hepatocellular carcinoma was not evenly distributed between the two CNI groups. Since some of the patients were treated before the Milan criteria were implemented, we performed a separate analysis of patient survival excluding patients who died of recurrent hepatocellular carcinoma, and the survival diff erence between tacrolimus and cyclosporine remained (data not shown).
We next performed Cox proportional hazards modeling to look for factors that may independently impact post-OLT survival and fi brosis progression (Table 3) . Multivariable analysis demonstrated cyclosporine use and preoperative MELD ≥21 to be the strongest predictors of decreased post-OLT survival. Since mycophenolate use was colinear with tacrolimus use, this factor was not included in our multivariable analysis. For advanced fi brosis or death from HCV recurrence, multivariable analysis revealed African American race, CMV infection, and acute cellular rejection >3 months post-OLT as predictive of this composite endpoint. As shown in Figure 2 , CNI choice did not impact HCV fi brosis progression.
Th e primary causes of death are listed in Table 4 . Overall, fewer deaths occurred in the tacrolimus-treated group, and therefore each cause of death was represented as a percentage of the total deaths. Recurrent HCV was the most common reason for death in both groups. Malignancy was twice as common in cyclosporine-treated patients as tacrolimus-treated patients; however, cyclosporine-treated patients had 13 deaths from recurrent hepatic malignancies unlike the tacrolimus group, which had 3. Malignancies other than recurrent hepatocellular carcinoma were not diff erent between CNI groups. Of note, 6% of cyclosporine-treated patients died from either acute or chronic rejection compared with none of the tacrolimus-treated patients.
DISCUSSION
Our results demonstrate that tacrolimus is a signifi cant independent predictor of survival in post-OLT HCV-infected patients. Many transplant physicians may fi nd these results unexpected. In fact, we launched this investigation because we anticipated the opposite result. Our program preferentially administered cyclosporine to HCV-infected patients with the belief that this change in immunosuppression would lead to better outcomes based on in vitro data. After analyzing the results of our study, we reviewed the literature and found that the most defi nitive studies comparing the eff ect of CNIs on survival of HCV-infected patients had short follow-up (typically 1 year). Forman et al demonstrated a higher rate of graft loss in HCV-infected patients and showed the different outcomes were not apparent until after the fi rst year of transplant (4). Berengeur et al published a meta-analysis comparing outcomes in HCV-infected liver transplant recipients and reported no diff erence in outcomes (25) . All but one of the reviewed studies in this report evaluated 1-year outcomes. Th e single study reporting 5-year follow-up yielded results that mirror ours (18) . Th is study was the long-term follow-up of the tacrolimus registration trial cohorts in which Survival based on presence of acute cellular rejection (ACR) (P = NS)
Cyclosporine: no ACR (n = 89) 84% 78% 66%
Tacrolimus: no ACR (n = 125) 93% 86% 78%
Cyclosporine: ACR (n = 159) 86% 80% 67%
Tacrolimus: ACR (n = 143) 88% 83% 73%
Survival based on presence of steroid-resistant rejection (SRR) (P = 0.007)
Cyclosporine: no SRR (n = 201) 87% 79% 65%
Tacrolimus: no SRR (n = 250) 92% 86% 77%
Cyclosporine: SRR (n = 47) 81% 81% 74%
Tacrolimus: SRR (n = 18) 72% 61% 56%
Survival by race (P = 0.04)
Cyclosporine: African American (n = 20) 90% 70% 55%
Tacrolimus: African American (n = 22) 95% 91% 77%
Cyclosporine: white (n = 187) 87% 81% 68%
Tacrolimus: white (n = 198) 88% 84% 74%
Cyclosporine: other (n = 41) 76% 73% 66%
Tacrolimus: other (n = 48) 94% 85% 79%
Survival by Model for End-Stage Liver Disease score (P = 0.002) Cyclosporine: 21+ (n = 39) 69% 67% 51%
Tacrolimus: 21+ (n = 51) 86% 80% 71%
Cyclosporine: <21 (n = 205) 88% 81% 69%
Tacrolimus: <21 (n = 214) 92% 86% 77% Figure 2 . Fibrosis progression to METAVIR stage 3 or 4 or death from recurrent hepatitis C by calcineurin inhibitor used.
Wiesner reported a signifi cantly higher survival associated with tacrolimus (78.9%) compared with cyclosporine (60.5%) in HCV-infected patients. Despite intriguing in vitro data that cyclosporine inhibits HCV viral replication, we must make post-OLT patient care decisions based on a drug's eff ect on patient survival and fibrosis progression (11) (12) (13) (14) . Th e survival diff erence was not explained by a diff erence in fi brosis progression. As expected from the fi brosis data, death due to recurrent disease was approximately the same in both groups. When evaluating the primary causes of death in the cyclosporine-treated group, rejection was higher in cyclosporine-than tacrolimus-treated patients. Th is is in line with previous data showing that cyclosporine-treated patients have a higher incidence of rejection and with recent data showing an increased risk of malignancy (17, 18, 21, 22) . We do not have accurate information on HCV treatment in this cohort and therefore cannot exclude that such treatment may have played a role in survival. However, if cyclosporine improved responsiveness to interferon therapy, we would have expected to see an improvement in survival or decreased fi brosis progression in these patients, which was not observed. Although the rejection rate was higher in the cyclosporine-treated patients, this does not explain the entire mortality diff erence. Since both HCV patients and non-HCV patients achieved a survival advantage with tacrolimus over cyclosporine, this may be a drug eff ect.
Of note, African Americans benefi ted the most from tacrolimus treatment, with an absolute 5-year survival advantage of 20%. As African American recipients have historically had shorter post-OLT survival compared with Caucasians, it is very intriguing that CNI choice may mitigate this diff erence to some extent (23) (24) (25) . However, the small number of African American recipients did not allow us to discern a reason for this diff erence. Th is observation requires confi rmation in a larger multicenter cohort.
One limitation of the study was that many of the patients treated with tacrolimus were also treated with mycophenolate mofetil. Th erefore, the individual eff ects of tacrolimus and mycophenolate mofetil could not be assessed.
Th e largest limitation of our study was its retrospective design, although the data were prospectively collected. Because of a programmatic protocol change in immunosuppression, fewer patients were treated with tacrolimus than cyclosporine before 2000, and after 2000 the opposite was true, with fewer patients treated with cyclosporine. Th is led to most patients being treated with tacrolimus in a diff erent era than those treated with cyclosporine. Th erefore, it is not possible to control for an "era" eff ect, as these two variables are colinear. Since the biggest diff erence between "eras" is likely immunosuppression and MELD at OLT (with the latter controlled for in multivariable modeling), we feel that our results remain valid despite this limitation.
In conclusion, tacrolimus aff ords HCV-infected post-OLT patients a long-term survival advantage over cyclosporine. CNI choice does not impact HCV fi brosis progression; however, tacrolimus does decrease the rate of rejection. Further study of CNI's impact on survival is needed in a larger multicenter cohort with long-term follow-up. 
